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24S SZAFER ET AL 
Sequence analysis of the joining regions VDJC of the two patients 
with patchy AA showed an interesting pattern in the diversity region. 
All the sequences shared one or two proline residues at the beginning 
of this region. In the control TCR V{318 sequences one proline residue 
was also found. In contrast, in the AU patient different and non-related 
sequences were found in the diversity region. 
Interestingly, one same motif was found in both patchy AA 
patients. Surprisingly, this CDRJ region specificity arose as a conse­
quence of two different J region rearrangements, suggesting a specific 
selected rearrangement rather than a random event, and possibly 
relevant to AA . We are in the process of extending the TCR V {3 
repertoire and sequencing analysis to other AA patients with relative 
recent onset of the disease, long-standing AA, and more controls. 
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T
he absence of obvious follicular destruction in alope­
cia areata (AA) lesions suggests that, if there is an 
autoimmune cytopathic effect against a constituent of 
the follicle itseH:' or an asso�iate structur: , its ta�get 
might be a functlonally crUCIal but numencally mmor 
cell population. There is increasing clinical, morphologic, and 
functional evidence suggesting a melanocyte involvement in AA: 1) 
the frequent association of AA with vitiligo, a condition in which 
autoimmune reactivity against melanocytes has been postulated; 2) 
the frequent sparing of nonpigmented hairs in AA lesions, even 
within an active patch; 3) the frequent lack of pigment in the initial 
phase of hair regrowth after remission; 4) the strucrnral damage 
shown by melanocytes within hair bulbs affected by early AA 
lesions and the epidermal and/or ocular hypopigmentation, which 
in some cases may occur parallel to the loss of follicular melano­
cytes; 5) the functional abnonnalities of the retinal pigment epithe­
lium reported in AA patients, even those without clinically evident 
pigment cell involvement; 6) the description of antibody reactivity 
in sera from AA patients against cultured melanoma cells. 
To search for evidence indicating that a specific autoimmune 
attack against melanocytes is a characteristic event in the develop­
ment of AA, we addressed the question whether or not sera from 
AA patients contain antibodies to specific cell-surface molecules of 
autologous and allogeneic melanocytes in culture. Because of 
previous reports of antimelanocyte antibodies in most cases of 
active vitiligo, melanocyte primary cultures were established from 
unaffected skin of four adult patients with vitiligo, three of whom 
also had current (one case) or past AA (Table I). Melanocytes from 
both the epidermal and dennal portions of the skin biopsies were 
cultured on coverslips, and the viable cells were used in single- and 
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Table I. The Study Patients 
Patient Sex/Age Alopecia Areata Vitiligo 
MUL F/40 First patch at Focal, on both knees and 
age 5; alope- ankles, since age 10 
cia universalis 
since age 12 
PAV F/46 One scalp patch Focal, on <10% body 
at age 16 surface, since age 22 
WYA F/52 Three scalp Extensive, on neck, 
patches at chest, back, hands, and 
age 42 toes, since age 14 
LEW F/58 None Extensive, on chest, axil-
lae, and groin since 
age 9 
double-label immunofluorescence stainings with autologous serum 
and sera from the other three tissue donors. 
In addition to these serum samples, 20 sera from patients with 
active AA were also tested on viable melanocytes cultured from 
neonatal foreskin (obtained from Clonetics). They included six 
recent-onset (less than 6 months) cases, with one or two scalp 
patches, and 14 long-standing (more than 18 months) cases, with 
25-99% of scalp hair loss. The presence of circulating melanocyte­
reactive antibodies was investigated on viable melanocytes from 
both autologous skin and neonatal foreskin by standard and com­
plement-fixing immunofluorescence (IF) techniques. Two different 
systems, using either fresh mouse or rabbit serum as a source of 
complement and labeled antibodies against mouse or rabbit C3, 
were employed in the complement-fixing IF procedures. 
As positive controls for human immunoglobulin binding, sera 
containing non-organ-specific autoantibodies against cytoplasmic 
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Table II. Double-Label IF Staining Results 
Monoclonal Neonatal Foreskin 
Antibodies Antigen Melanocytes 
BM-63 {32 micro globulin +++ (surt."1ce) on all cells 
L243 HLA-DR Negative 
TA99 (MEL-5) Mature melanosomes + + + (cytoplasmic) on 
>95% of cells 
WM-9 Human nerve growth + to + + + (surface) on 
factor receptor -20% of cells 
or nuclear antigens were used. To conclusively identifY differenti­
ated melanocytes in primary cultures of epidermal cells from the 
four donors, double-label IF stainings with the autologous serum 
and MEL-5, anti-nerve growth factor receptor or anti-major 
histocompatibility monoclonal antibodies were also performed 
(Table II). 
In the four cases studied, no cell-surface antibody binding from 
any of the donor's sera against viable autologous melanocytes was 
found, by either standard or complement-fixing IF. Moreover, 
neither these four sera nor any of 20 sera from patients with active 
AA was positive for cell-surface IF reactivity on viable neonatal 
foreskin melanocytes by standard IF staining. In contrast to the lack 
of cell-surface reactivity, nuclear and/or cytoplasmic binding on 
fixed and permeabilized cells was detected in some cases. 
To further confirm that the lack of cell-surface binding was not 
due to the particular selection of sera employed, we also tested a 
serum sample, kindly provided by Dr. J.-c. Bystryn, New York 
University, which had been previously found to produce comple-
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ment-mediated cytOtOXlClty on human melanocytes in culture 
a.-c. Bystryn, personal communication). Again, this serum did not 
show any detectable cell-surface binding on viable melanocytes 
cultured from all four donors or from neonatal foreskin, either in 
standard or complement-fixing IF stainings at 1:5 and 1:2 dilutions, 
respectively. 
These negative results argue against melanocytes being the 
target of autoimmunity in AA. Alternatively, they may be the 
result of 1) loss of autoantigen expression by cultured melano­
cytes, 2) antigenic differences between follicular and epidermal 
melanocytes, or 3) the autoimmune attack in AA being exclu­
sively mediated by T-cell (and not autoantibody-dependent) 
mechanisms. 
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T
he thymus gland is regarded as the prime develop­
mental organ educating thymocytes to distinguish 
"self" from "nonself," producing T lymphocytes and 
providing them with specific antigen-recoguizing 
receptors. In addition to being a lymphocyte-differ­
entiatIng gland it is also an endocrine organ producing several 
hormones. Thymulin, a nonapeptide produced by the gland, is a 
hormone involved in T -lymphocyte differentiation that is released 
by pituitary factors. Although the pathogenesis of alopecia areata is 
unclear all evidence suggests an autoimmune etiology; there is also 
an increased incidence in Down's Syndrome, hypothymic or athymic. 
We studied 77 patients with alopecia areata (48 patchy disease, 
12 alopecia totalis, and 17 alopecia universalis) measuring early 
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morning plasma thymulin levels using a radioimmunoassay com­
paring 64 normal age- and sex-matched controls. 
The results demonstrated a significant decrease in plasma thymu­
lin levels in normal controls over 20 years of age, although older 
patients still had detectable levels with a mean thymulin of 371 
Fg/mL The alopecia areata patients as a group had low thymulin 
levels; 75% of patients with alopecia areata over 20 years of age had 
thymulin levels below the normal mean value. In patients with 
patchy alopecia areata over 20 years of age, 12 had undetectable 
levels, and the remainder a low mean plasma thymulin of 296 
Fg/ml (p < 0.00001). Ninety percent of alopecia areata patients less 
than 20 years of age had plasma thymulin levels below the control 
mean (1080 Fg/ml). There was no correlation between the pres­
ence of circulating organ-specific antibodies or atopic disease and 
thymulin levels. When the extent of disease was studied, mean 
levels were dearly lowered in patients with patchy alopecia areata, 
further depressed in alopecia totalis, and often undetectable in 
0022-202X/95/$09.50 ' SSDIO022-202X(95)00119-6 ' Copyright © 1995 by The Society for Investigative Dermatology, Inc. 
